May 30, 2025 11:46 AM EDT

Summit’s disappointing survival readout raises stakes for full data

Max Gelman

Senior Editor

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data?

The biotech on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Summit’s disappointing survival readout raises stakes for full data

Max Gelman

Senior Editor

Sign up to read this article for free.

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Max Gelman

Senior Editor

Sign up to read this article for free.

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Summit’s disappointing survival readout raises stakes for full data

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

From weeks to days: how Aizon Intelligent Agents transform pharma validation